Infracordal Stenosis: A Glucocorticoid‐Responsive Subtype of Autoimmune Laryngotracheal Stenosis
The Laryngoscope · 2026
DOI: 10.1002/lary.70418 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2026. Verfasst von Brendan Denvir und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Laryngostenosis, Glucocorticoids, Autoimmune Diseases, Tracheal Stenosis. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIDCD NIH HHS, Jerome L. Greene Foundation.
Abstract (Originalsprache)
Objective
As our understanding of autoimmune laryngotracheal stenosis (LTS) evolves, distinguishing patients who may benefit from systemic immunosuppression versus those needing only local treatment is increasingly important. In this study, we identify a distinct subset of autoimmune LTS characterized by edema of the inferior true vocal folds that extends to the superior aspect of the cricoid cartilage, termed “infracordal stenosis.” The objective of this study is to characterize the clinical presentation and treatment outcomes of infracordal stenosis and compare it to typical autoimmune‐related subglottic stenosis (AI‐SGS).
Methods
We conducted a retrospective review of patients with autoimmune laryngotracheal stenosis evaluated by both rheumatology and otolaryngology at our institution to identify two groups: patients with infracordal stenosis and those with typical AI‐SGS. Data on immunosuppressive treatments and airway dilation procedures were collected. Time to first dilation was compared between groups.
Results
Among 49 patients with autoimmune LTS, 11 had infracordal involvement. Six patients had isolated infracordal stenosis while five had concomitant subglottic involvement. Kaplan–Meier analysis showed longer time to first dilation in patients with infracordal involvement (median 792 vs. 44 days; p = 0.048). Four out of six patients with isolated infracordal stenosis required no dilations during their entire follow‐up period.
Conclusion
Among autoimmune LTS patients referred to rheumatology, those with infracordal involvement experienced longer time to first dilation compared to those with typical AI‐SGS. These findings suggest that infracordal stenosis may represent a distinct, glucocorticoid‐responsive phenotype within autoimmune laryngotracheal stenosis, with implications for treatment selection and multidisciplinary care. Level of Evidence 4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Brendan Denvir, Bridget Burgess, Kevin Motz, Simon R A Best, Lee M Akst, Alexander T Hillel
Förderung
- NIAMS NIH HHS
- NIDCD NIH HHS
- Jerome L. Greene Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Denvir, B., Burgess, B., Motz, K., Best, S. R. A., Akst, L. M., Antiochos, B., Seo, P., & Hillel, A. T. (2026). Infracordal Stenosis: A Glucocorticoid‐Responsive Subtype of Autoimmune Laryngotracheal Stenosis. The Laryngoscope. https://doi.org/10.1002/lary.70418
Vancouver
Denvir B, Burgess B, Motz K, Best SRA, Akst LM, Antiochos B, et al. Infracordal Stenosis: A Glucocorticoid‐Responsive Subtype of Autoimmune Laryngotracheal Stenosis. The Laryngoscope. 2026. doi:10.1002/lary.70418
BibTeX
@article{Denvir2026,
author = {Denvir, Brendan and Burgess, Bridget and Motz, Kevin and Best, Simon R A and Akst, Lee M and Antiochos, Brendan and Seo, Philip and Hillel, Alexander T},
title = {Infracordal Stenosis: A Glucocorticoid‐Responsive Subtype of Autoimmune Laryngotracheal Stenosis},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.70418}
}
EUVIMED